West Pharmaceutical (WST) | Financial Analysis & Statements
West Pharmaceutical Services Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
805.0M
Gross Profit
303.9M
37.75%
Operating Income
175.1M
21.75%
Net Income
132.1M
16.41%
EPS (Diluted)
$1.82
Balance Sheet Metrics
Total Assets
4.3B
Total Liabilities
1.1B
Shareholders Equity
3.2B
Debt to Equity
0.34
Cash Flow Metrics
Operating Cash Flow
185.7M
Free Cash Flow
175.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
West Pharmaceutical Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.1B | 2.9B | 2.9B | 2.9B | 2.8B |
| Cost of Goods Sold | 2.0B | 1.9B | 1.8B | 1.8B | 1.7B |
| Gross Profit | 1.1B | 998.5M | 1.1B | 1.1B | 1.2B |
| Gross Margin % | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% |
| Operating Expenses | |||||
| Research & Development | 74.3M | 69.1M | 68.4M | 58.5M | 52.8M |
| Selling, General & Administrative | 393.6M | 338.5M | 353.4M | 316.9M | 362.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 467.9M | 407.6M | 421.8M | 375.4M | 415.6M |
| Operating Income | 636.1M | 590.9M | 707.4M | 760.8M | 760.2M |
| Operating Margin % | 20.7% | 20.4% | 24.0% | 26.4% | 26.8% |
| Non-Operating Items | |||||
| Interest Income | 17.5M | 19.6M | 28.0M | 5.1M | 1.0M |
| Interest Expense | - | 3.0M | 9.0M | 7.9M | 8.2M |
| Other Non-Operating Income | -52.2M | -22.0M | -28.4M | -78.1M | -4.1M |
| Pre-tax Income | 600.9M | 585.5M | 698.0M | 679.9M | 748.9M |
| Income Tax | 121.6M | 107.5M | 122.3M | 114.7M | 107.2M |
| Effective Tax Rate % | 20.2% | 18.4% | 17.5% | 16.9% | 14.3% |
| Net Income | 493.7M | 492.7M | 593.4M | 585.9M | 661.8M |
| Net Margin % | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% |
| Key Metrics | |||||
| EBITDA | 822.7M | 764.0M | 875.7M | 835.8M | 885.6M |
| EPS (Basic) | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 |
| EPS (Diluted) | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
| Basic Shares Outstanding | 72300000 | 73000000 | 74300000 | 74400000 | 74400000 |
| Diluted Shares Outstanding | 72300000 | 73000000 | 74300000 | 74400000 | 74400000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
West Pharmaceutical Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 791.3M | 484.6M | 853.9M | 894.3M | 762.6M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 574.4M | 552.5M | 512.0M | 507.4M | 489.0M |
| Inventory | 443.9M | 377.0M | 434.7M | 414.8M | 378.4M |
| Other Current Assets | 168.6M | 124.0M | 135.8M | 103.0M | 112.0M |
| Total Current Assets | 2.0B | 1.5B | 1.9B | 1.9B | 1.7B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 296.4M | 274.0M | 263.7M | 258.9M | 208.8M |
| Goodwill | 227.7M | 223.0M | 232.1M | 233.0M | 242.8M |
| Intangible Assets | 7.7M | 10.8M | 15.1M | 18.4M | 23.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 118.5M | 100.3M | 47.0M | 104.0M | 87.7M |
| Total Non-Current Assets | 2.3B | 2.1B | 1.9B | 1.7B | 1.6B |
| Total Assets | 4.3B | 3.6B | 3.8B | 3.6B | 3.3B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 253.7M | 239.3M | 242.4M | 215.4M | 232.2M |
| Short-term Debt | 22.7M | 17.9M | 151.7M | 18.2M | 53.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 55.6M | 57.4M | 39.5M | 32.1M | 29.3M |
| Total Current Liabilities | 654.9M | 550.4M | 671.8M | 519.0M | 594.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 298.4M | 284.4M | 157.3M | 299.7M | 271.8M |
| Deferred Tax Liabilities | 23.0M | 20.5M | 12.7M | 14.3M | 4.9M |
| Other Non-Current Liabilities | 75.2M | 62.2M | 58.5M | 51.6M | 38.2M |
| Total Non-Current Liabilities | 439.1M | 410.7M | 276.7M | 412.9M | 384.3M |
| Total Liabilities | 1.1B | 961.1M | 948.5M | 931.9M | 978.4M |
| Equity | |||||
| Common Stock | 18.8M | 18.8M | 18.8M | 18.8M | 18.8M |
| Retained Earnings | 4.4B | 4.0B | 3.5B | 3.0B | 2.5B |
| Treasury Stock | 1.1B | 1.1B | 637.6M | 370.9M | 229.5M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.2B | 2.7B | 2.9B | 2.7B | 2.3B |
| Key Metrics | |||||
| Total Debt | 321.1M | 302.3M | 309.0M | 317.9M | 325.3M |
| Working Capital | 1.3B | 987.7M | 1.3B | 1.4B | 1.1B |
Balance Sheet Composition
West Pharmaceutical Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 493.7M | 492.7M | 593.4M | 585.9M | 661.8M |
| Depreciation & Amortization | 171.4M | 155.4M | 137.3M | 120.6M | 122.3M |
| Stock-Based Compensation | 23.8M | 18.7M | 23.3M | 23.7M | 37.5M |
| Working Capital Changes | 79.8M | 2.9M | -20.4M | -15.0M | -198.1M |
| Operating Cash Flow | 753.0M | 661.5M | 772.1M | 697.7M | 579.2M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | 0 | 0 | -2.2M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | - | -1.7M | -6.7M | -3.6M | 300.0K |
| Financing Activities | |||||
| Share Repurchases | -136.8M | -566.6M | -451.2M | -222.2M | -151.9M |
| Dividends Paid | -61.2M | -59.1M | -57.0M | -54.1M | -51.1M |
| Debt Issuance | 0 | 164.7M | - | - | 0 |
| Debt Repayment | -1.1M | -192.3M | -2.3M | -44.3M | -2.2M |
| Financing Cash Flow | -203.3M | -655.3M | -510.6M | -321.8M | -205.2M |
| Free Cash Flow | 468.9M | 276.4M | 414.5M | 439.4M | 330.6M |
| Net Change in Cash | 549.7M | 4.5M | 254.8M | 372.3M | 374.3M |
Cash Flow Trend
West Pharmaceutical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
40.99
Forward P/E
32.05
Price to Book
6.94
Price to Sales
6.72
PEG Ratio
0.74
Profitability Ratios
Profit Margin
16.85%
Operating Margin
21.70%
Return on Equity
19.13%
Return on Assets
11.21%
Financial Health
Current Ratio
2.71
Debt to Equity
10.73
Beta
1.15
Per Share Data
EPS (TTM)
$7.47
Book Value per Share
$44.11
Revenue per Share
$44.63
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| WST | 22.1B | 40.99 | 6.94 | 19.13% | 16.85% | 10.73 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
| ResMed | 32.0B | 21.69 | 5.06 | 25.68% | 27.53% | 13.41 |
| Hologic | 17.0B | 31.54 | 3.23 | 10.86% | 13.18% | 48.05 |
Financial data is updated regularly. All figures are in the company's reporting currency.






